Actim®
ELISA SARS-CoV-2 IgG

Efficient and reliable mass testing of recent COVID-19 infection

Actim ELISA SARS-CoV-2 IgG offers laboratories a highly sensitive and specific method to detect a recent COVID-19 infection. The test provides quantitative results in less than 2 hours for pandemic analysis, disease control measures, and vaccine development.



actimtest.com

Efficient pandemic analysis

As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, has spread through the world's population, effective testing tools are needed. Actim ELISA SARS-CoV-2 IgG allows mass testing of recent infections, retrospective tracing of infection chains, and assessment of the proportion of asymptomatic infections. The test provides critical information about the prevalence of SARS-CoV-2 infection, which is essential for both local and global monitoring of the pandemic and tracking of population immunity.

Actim ELISA SARS-CoV-2 IgG can be used as a comparison method for development of serological COVID-19 tests, and to measure immune response to vaccines against SARS-CoV-2.

Based on highly specific detection of immune reaction

The Actim ELISA SARS-CoV-2 IgG test is based on detecting the immune response against the SARS-CoV-2 virus. The test is an enzyme-linked immunosorbent assay (ELISA) which measures the specific IgG antibodies against the spike glycoprotein S1 (S1 protein) found on the surface of the SARS-CoV-2 virus. The antibodies in a positive serum sample bind with high specificity to the test plate coated with SARS-CoV-2 S1 proteins.

Detection antibody (HRP-conjugated anti-human IgG)

IgG antibody in a positive serum sample

Antigen (S1 protein) on a plate

The detection of antibodies against SARS-CoV-2 virus with Actim ELISA SARS-CoV-2 IgG.

First-class specificity and sensitivity

The Actim ELISA SARS-CoV-2 IgG detects recent COVID-19 infection with outstanding specificity (98%) and sensitivity (96%) (Table 1), and is one of the most reliable serological COVID-19 ELISA tests on the market (Table 2). The test is specific to SARS-CoVs and does not cross-react with IgG antibodies against other common viruses, such as influenza A and B.

Table 1. Excellent performance of Actim ELISA SARS-CoV-2- IgG compared to RT-PCR in analysis of total 670 serum samples (≥ 7 days after PRC sampling).

Sensitivity	Specificity	PPV	NPV	Accuracy
96%	98%	87%	99%	98%

Table 2. Actim ELISA SARS-CoV-2 IgG has best-in-class sensitivity (n=50 positive and 50 negative).

Method	Specificity
Actim ELISA SARS-CoV-2 IgG 51	96 %
ELISA IgG, Competitor A	70 %
ELISA IgG, Competitor B	72 %
ELISA IgG, Competitor C	80 %

Actim ELISA SARS-CoV-2 IgG

- Detects recent COVID-19 infection, from **one week to several months after infection onset**
- Detects **symptomless** infections
- **96%** sensitivity and **98%** specificity against RT-PCR
- Highly specific to SARS-CoVs in **cross-reactivity tests**
- Test kit contains **all necessary reagents** for testing
- Developed and produced in **Finland**

Quantitative results in less than 2 hours

Before you begin

Mix all reagents gently.



Dilute Wash Solution to a final volume.



Dilute Samples, Controls, and Calibrators.



Dilute HRP-Conjugate in Conjugate Diluent.

Test procedure



Add diluted Samples/ Controls/ Calibrators to appropriate wells and incubate the plate.

Wash the plate twice.

Add diluted HRP-Conjugate to each well and incubate the plate.

Wash the plate six times.



Add Substrate to each well and incubate the plate.



Add Stop Solution to each well.



Read the plate at 450 nm.

Contact us

Ordering information

Actim ELISA SARS-CoV-2 IgG	35530ETAC

Actim – a part of Medix Biochemica
Klovinpellontie 3, FI-02180 Espoo, Finland
actim@actimtest.com

www.actimtest.com

Product availability and/or labeling may vary from country to country and is subject to varying regulatory requirements. Please contact your local representative for availability.
© 01/2021 Actim Oy. All rights reserved. Actim is a registered trademark of Actim Oy.